What is ProPhase Labs Financial Strength?
ProPhase Labs has the Financial Strength Rank of 4.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
ProPhase Labs did not have earnings to cover the interest expense.
ProPhase Labs's debt to revenue ratio for the quarter that ended in Mar. 2024 was 1.61.
As of today, ProPhase Labs's Altman Z-Score is 0.64.
Competitive Comparison of ProPhase Labs's Financial Strength
For the Diagnostics & Research subindustry, ProPhase Labs's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs's Financial Strength Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Financial Strength distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Financial Strength falls into.
ProPhase Labs Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
ProPhase Labs's Interest Expense for the
months ended in Mar. 2024 was $-0.52 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-8.30 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $18.16 Mil.
ProPhase Labs's Interest Coverage for the quarter that ended in Mar. 2024 is
| ProPhase Labs did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
ProPhase Labs's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
ProPhase Labs has a Z-score of 0.64, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of 0.64 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (ProPhase Labs) Business Description
Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
| Morse Robert A. Jr. |
officer: Controller |
711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530 |
| Billy Joe White |
officer: Chief Financial Officer |
191 OTTO ST., PORT TOWNSEND WA 98368 |
| Jason Michael Barr |
director |
902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010 |
| Louis Md Gleckel |
10 percent owner |
C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042 |
| Ted William Karkus |
10 percent owner |
188 HEWLETT NECK ROAD, WOODMERE NY 11598 |
| Warren Hirsch |
director |
621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901 |
| Monica L. Brady |
officer: Chief Accounting Officer |
621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901 |
| Cuddihy Robert V Jr |
officer: Chief Operating Officer |
PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017 |
| Braden Michael Leonard |
10 percent owner |
156 S. FIRST STREET, ZIONSVILLE IN 46077 |
| Mark S Leventhal |
10 percent owner |
THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468 |
| Mark Shawn Frank |
director |
104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940 |
| James T Mccubbin |
director |
|
| Mark A. Burnett |
10 percent owner |
40 HEMLOCK DRIVE, ROSLYN NY 11576 |
| Guy J Quigley |
director, 10 percent owner, officer: Chairman, President, CEO |
C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901 |
| John Deshazo |
10 percent owner |
17 WOLCOTT COURT, BOSTON MA 02136 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRPH has been successfully added to your